Ascendis Pharma A/S Ordinary Share (ASND)
Stock · NASDAQ · Health Care
$248.06as of 8/28/2026
Price chart
Open in TradingViewActive signals
Resistance level
$252.11
Industry
Biotechnology: Pharmaceutical Preparations
About ASND
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipe…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 1,189
- Website
- ascendispharma.dk/
Fundamentals
- 1-day range
- $246.3$250.23
- Market cap
- $15.49B
- P/E (trailing)
- 26.94
- P/E (forward)
- 26.07
- EPS (trailing)
- $7.59
- Dividend yield
- —
- Beta
- 0.33
- Avg. volume
- 653.4K
52-week range
$186.05$282.15
Next earnings: April 30, 2026 · EPS estimate $0.43After Closeconfirmed
Forecasts
19 analyst ratings
Buy 96%
Hold 4%
Sell 0%
1-year price forecast
High
$361.59
+45.8%
Median
$307.21
+23.8%
Low
$270.22
+8.9%
Ascendis Pharma A/S Ordinary Share Competitors
Chosen by industry and closest market cap.
- ASNDAscendis Pharma A/S Ordinary Share$248.06▼ 0.52%Market cap $15.49BP/E 26.94$186.05$282.15
- BBIOBridgeBio Pharma Inc. Common Stock$76.62▼ 2.62%Market cap $16.20BP/E —$48.78$93.42
- JAZZJazz Pharmaceuticals plc Common Stock (Ireland)$244.6▼ 2.59%Market cap $16.66BP/E 16.97$123.88$266.38
- ELANElanco Animal Health Incorporated Common Stock$24.12▼ 1.51%Market cap $12.09BP/E —$17.11$27.98
- VTRSViatris Inc. Common Stock$16.34▼ 3.26%Market cap $18.97BP/E —$9.43$18.39
- MDGLMadrigal Pharmaceuticals Inc. Common Stock$534.12▼ 1.76%Market cap $11.79BP/E —$393.61$615
- ABVXAbivax SA American Depositary Shares$113.41▼ 0.78%Market cap $11.19BP/E —$60.45$139
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ASND Ascendis Pharma A/S Ordinary Share | $15.49B | 26.94 | $248.06 | ▼ 0.52% | $186.05$282.15 |
| BBIO BridgeBio Pharma Inc. Common Stock | $16.20B | — | $76.62 | ▼ 2.62% | $48.78$93.42 |
| JAZZ Jazz Pharmaceuticals plc Common Stock (Ireland) | $16.66B | 16.97 | $244.6 | ▼ 2.59% | $123.88$266.38 |
| ELAN Elanco Animal Health Incorporated Common Stock | $12.09B | — | $24.12 | ▼ 1.51% | $17.11$27.98 |
| VTRS Viatris Inc. Common Stock | $18.97B | — | $16.34 | ▼ 3.26% | $9.43$18.39 |
| MDGL Madrigal Pharmaceuticals Inc. Common Stock | $11.79B | — | $534.12 | ▼ 1.76% | $393.61$615 |
| ABVX Abivax SA American Depositary Shares | $11.19B | — | $113.41 | ▼ 0.78% | $60.45$139 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursdaybenzinga · 8/27/2026
- This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For ThursdayBenzinga · 8/27/2026
- HC Wainwright & Co. Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $345Benzinga · 8/27/2026
- If You Invested $1000 In Ascendis Pharma Stock 10 Years Ago, You Would Have This Much TodayBenzinga · 8/26/2026
- BMO Capital Initiates Coverage On Ascendis Pharma with Outperform Rating, Announces Price Target of $319Benzinga · 8/19/2026
- TD Cowen Maintains Buy on Ascendis Pharma, Raises Price Target to $341Benzinga · 8/14/2026
- RBC Capital Maintains Outperform on Ascendis Pharma, Raises Price Target to $290Benzinga · 8/14/2026
- Barclays Maintains Overweight on Ascendis Pharma, Lowers Price Target to $329Benzinga · 8/14/2026
- Ascendis Pharma A/S (ASND) Q2 2026 Earnings Call TranscriptSeekingAlpha · 8/13/2026
Insider Activity
Insider Actions →Acquired
850
Disposed
19.5K
- Scott Thomas Smith · June 2, 2026 · Buy100 @ $219
- Scott Thomas Smith · May 29, 2026 · Buy250 @ $223.32
- Jean Jacques Bienaime · May 29, 2026 · Buy100 @ $223.5
- Jean Jacques Bienaime · May 29, 2026 · Buy200 @ $223.76
- Jean Jacques Bienaime · May 26, 2026 · Buy200 @ $236.24
- Flemming Steen Jensen · May 11, 2026 · Sale19.5K @ $238.49
See the full, filterable feed with live charts on the MarketWall dashboard.